By Chris Wack
Nano-X Imaging shares were 10% higher, at $4.93, after the company said it has received 510(k) clearance from the Food and Drug Administration for the Nanox.ARC X, its new multi-source digital tomosynthesis system.
The medical technology company said the FDA 510(k) clearance was received in less than 30 days from the date of submission.
The 510(k) clearance covers the production of tomographic images for general use, including the human musculoskeletal system and pulmonary, intra-abdominal and paranasal sinus indications, adjunctive to conventional radiography on adult patients.
Nano-X said the Nanox.ARC X is designed to be installed in any standard X-ray shielded room with minimal infrastructure requirements. The system operates on standard power and features a cable-free design for enhanced user and patient safety, ease of cleaning and maintenance.
Nanox will offer the Nanox.ARC X system later this year.
The stock hit its 52-week low of $3.75 on April 7, and is down 47% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 17, 2025 10:47 ET (14:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。